LIXTE Biotechnology Holdings, Inc. is making strides in cancer therapy with their breakthrough Protein Phosphatase 2A inhibitor, LB-100. The compound is being tested in trials for Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer. The company aims to disrupt traditional cancer treatments with LB-100, which sensitizes tumors to chemotherapy, radiation, and immunotherapy. With potential catalysts expected in the second half of 2025, LIXTE is positioned to address high-unmet needs in the global oncology market, projected to reach $200 billion by 2025.

In their Phase 1B/2 trials, LIXTE is exploring the effectiveness of LB-100 in combination with different drugs for Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer. These aggressive and difficult-to-treat types of cancers represent a significant portion of global oncology cases, with limited targeted therapies available. LIXTE’s innovative approach to cancer therapy has the potential to revolutionize treatment options for patients facing resistant cancers.

Read more at GlobeNewswire: LIXTE Biotech Advances Precision Oncology